December 2019

imipenem/cilastatin plus relebactam was approved for the treatment of cUTIs and cIAIs in adult patients with limited or no available treatment options.

This approval allows ceftolozane/tazobactam to be used to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

Something novel in infectious diseases practice has occurred and, like many big changes, it is not without controversy.

In August, the FDA approved lefamulin (Xenleta) for the treatment of CABP after results from 2 phase 3 studies showed that the novel antibiotic was noninferior to existing treatment options.

In April, the US Food and Drug Administration (FDA) approved dolutegravir plus lamivudine as a complete 2-drug regimen for treatment naïve adults with HIV-1.

As the antibiotic pipeline produces new therapies, clinicians must understand each agent’s specific role in manage­ment of patients infected by multidrug-resistant pathogens.

A patient with HIV and skin lesions should trigger a broad differential.

If resources and funds were unlimited, what would the ideal stewardship program look like?

An epidemiologist explores the changing epidemiology of a familiar disease.

Novel modes of delivery are imperative to improve HIV suppression and prevent transmission.

The quick Pitt Bacteremia Score offers accuracy comparable to the original version's across multiple infections, and maintains ease of use.

Infectious diseases clinicians turn to Twitter as a tool for education and collaboration.

Bezlotoxumab, a human monoclonal anti­body directed against Clostridioides diffi­cile toxin B, is currently indicated for the prevention of recurrent C diffi­cile infection

In 2017, a guideline update stripped metronidazole of its first-line therapy designation and crowned oral vancomycin as initial therapy for all C difficile infection cases.

A total of 168,420 dental visits included antibiotic prophylaxis, 136,177 (80%) of which were deemed unnecessary.

Microarray patches could be key to providing a self-delivery system, that is also discreet, to administer HIV prevention and contraception to women in low-resource settings.

Investigators observed no moderate, severe, cumulative, or dose-limiting adverse events leading to discontinuation, and ACX-362E was generally well-tolerated at all dose levels.

Investigators assessed rates of all-cause mortality at Day 14 for Cefiderocol and meropenem in patients with nosocomial gram-negative pneumonia.

Experts provide community physicians treating HIV with practical advice for screening, diagnosing, and managing patients with HIV.